Morgan Stanley Caladrius Biosciences, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	BUY	$0.41 - $0.74 $31 - $57	78 Added 0.27%	28,775 $15,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $0.74 $31 - $57	78 Added 0.27%	28,775 $15,000
Q1 2022 Oct 27, 2022	SELL	$0.63 - $1.03 $49 - $80	-78 Reduced 0.27%	28,697 $21,000
Q1 2022 May 13, 2022	SELL	$0.63 - $1.03 $23,533 - $38,475	-37,355 Reduced 56.55%	28,697 $21,000
Q4 2021 Feb 14, 2022	BUY	$0.83 - $1.22 $11,372 - $16,716	13,702 Added 26.17%	66,052 $55,000
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $60,202 - $82,189	52,350 New	52,350 $64,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.